A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors

Trial Profile

A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Sapanisertib (Primary) ; Bevacizumab
  • Indications Endometrial cancer; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2016.
    • 22 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2017.
    • 23 Oct 2016 Planned number of patients changed from 60 to 23.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top